Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (5184)	12/20/2001 1:35:10 PM
From: Michael Young	Read Replies (2) of 52153

Good points. But us KOSP investors said the same things when Niaspan was introduced in 1997. But it turned out that the company couldn't come even close to turning a profit marketing that drug alone. It just seems that you can't gain much momentum in the lipid disorder market without a big, aggressive sales force. I don't think KOSP is a goner by any means. I was just considering a short to the lower 20s, upper teens while the market absorbs the disappointing news. But at this point I'll just sit back and wait for the sales results. If they are strong I'll probably get back in the stock. I don't think there is any hurry now. MIKE

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next